179 related articles for article (PubMed ID: 25611586)
1. The effect of therapeutic vaccination for the treatment of chronic hepatitis B virus infection.
Lee YB; Lee JH; Kim YJ; Yoon JH; Lee HS
J Med Virol; 2015 Apr; 87(4):575-82. PubMed ID: 25611586
[TBL] [Abstract][Full Text] [Related]
2. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy.
Seto WK; Wong DK; Fung J; Huang FY; Lai CL; Yuen MF
Hepatology; 2013 Sep; 58(3):923-31. PubMed ID: 23468172
[TBL] [Abstract][Full Text] [Related]
3. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.
Wong DK; Seto WK; Fung J; Ip P; Huang FY; Lai CL; Yuen MF
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1004-10.e1. PubMed ID: 23376799
[TBL] [Abstract][Full Text] [Related]
4. Long-term entecavir therapy results in falls in serum hepatitis B surface antigen levels and seroclearance in nucleos(t)ide-naïve chronic hepatitis B patients.
Hara T; Suzuki F; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Kumada H
J Viral Hepat; 2014 Nov; 21(11):802-8. PubMed ID: 25274427
[TBL] [Abstract][Full Text] [Related]
5. Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection.
Tsuge M; Hiraga N; Uchida T; Kan H; Miyaki E; Masaki K; Ono A; Nakahara T; Abe-Chayama H; Zhang Y; Naswa MG; Kawaoka T; Miki D; Imamura M; Kawakami Y; Aikata H; Ochi H; Hayes CN; Chayama K
J Gastroenterol; 2016 Nov; 51(11):1073-1080. PubMed ID: 26943168
[TBL] [Abstract][Full Text] [Related]
6. Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B.
Jeng WJ; Chen YC; Chien RN; Sheen IS; Liaw YF
Hepatology; 2018 Aug; 68(2):425-434. PubMed ID: 29108132
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis B surface antigen seroclearance in patients with chronic hepatitis B infection: a clinical study.
Ruan P; Xu SY; Zhou BP; Huang J; Gong ZJ
J Int Med Res; 2013 Oct; 41(5):1732-9. PubMed ID: 23908397
[TBL] [Abstract][Full Text] [Related]
8. Viral determinants predicting hepatitis B surface antigen (HBsAg) seroclearance in HIV-/HBV-coinfected patients.
Strassl R; Reiberger T; Honsig C; Payer BA; Mandorfer M; Grabmeier-Pfistershammer K; Rieger A; Kundi M; Grundtner P; Peck-Radosavljevic M; Popow-Kraupp T
J Viral Hepat; 2014 Jul; 21(7):508-16. PubMed ID: 24112778
[TBL] [Abstract][Full Text] [Related]
9. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B surface antigen seroclearance: Relationship to hepatitis B e-antigen seroclearance and hepatitis B e-antigen-negative hepatitis.
Fung J; Wong DK; Seto WK; Kopaniszen M; Lai CL; Yuen MF
Am J Gastroenterol; 2014 Nov; 109(11):1764-70. PubMed ID: 25244963
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of hepatitis B virus (HBV) vaccination in treating lamivudine-resistant HBV reactivation following hepatitis B surface antigen seroconversion.
Gérolami R; Borentain P; Colson P; Norguet E; Gérolami A; Tamalet C
Liver Int; 2007 Dec; 27(10):1417-21. PubMed ID: 18036104
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic vaccination in the immunotolerant phase of children with chronic hepatitis B infection.
Dikici B; Kalayci AG; Ozgenc F; Bosnak M; Davutoglu M; Ece A; Ozkan T; Ozeke T; Yagci RV; Haspolat K
Pediatr Infect Dis J; 2003 Apr; 22(4):345-9. PubMed ID: 12690275
[TBL] [Abstract][Full Text] [Related]
13. A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection.
Liu J; Lee MH; Batrla-Utermann R; Jen CL; Iloeje UH; Lu SN; Wang LY; You SL; Hsiao CK; Yang HI; Chen CJ
J Hepatol; 2013 May; 58(5):853-60. PubMed ID: 23246508
[TBL] [Abstract][Full Text] [Related]
14. Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial--ANRS HB02 VAC-ADN.
Fontaine H; Kahi S; Chazallon C; Bourgine M; Varaut A; Buffet C; Godon O; Meritet JF; Saïdi Y; Michel ML; Scott-Algara D; Aboulker JP; Pol S;
Gut; 2015 Jan; 64(1):139-47. PubMed ID: 24555998
[TBL] [Abstract][Full Text] [Related]
15. Predictors of HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients.
Kwak MS; Cho EJ; Jang ES; Lee JH; Yu SJ; Kim YJ; Yoon JH; Lee HS
Digestion; 2011; 84 Suppl 1():23-8. PubMed ID: 22156482
[TBL] [Abstract][Full Text] [Related]
16. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.
Boni C; Laccabue D; Lampertico P; Giuberti T; Viganò M; Schivazappa S; Alfieri A; Pesci M; Gaeta GB; Brancaccio G; Colombo M; Missale G; Ferrari C
Gastroenterology; 2012 Oct; 143(4):963-73.e9. PubMed ID: 22796241
[TBL] [Abstract][Full Text] [Related]
17. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study.
Liu J; Yang HI; Lee MH; Lu SN; Jen CL; Wang LY; You SL; Iloeje UH; Chen CJ;
Gastroenterology; 2010 Aug; 139(2):474-82. PubMed ID: 20434450
[TBL] [Abstract][Full Text] [Related]
18. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.
Reijnders JG; Perquin MJ; Zhang N; Hansen BE; Janssen HL
Gastroenterology; 2010 Aug; 139(2):491-8. PubMed ID: 20381492
[TBL] [Abstract][Full Text] [Related]
19. The lack of effect of therapeutic vaccination with a pre-S2/S HBV vaccine in the immune tolerant phase of chronic HBV infection.
Yalcin K; Danis R; Degertekin H; Alp MN; Tekes S; Budak T
J Clin Gastroenterol; 2003 Oct; 37(4):330-5. PubMed ID: 14506391
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of intrahepatic hepatitis B virus covalently closed circular DNA and total DNA in patients with acute hepatitis B and patients with chronic hepatitis B receiving anti‑viral treatment.
Ruan P; Zhou B; Dai X; Sun Z; Guo X; Huang J; Gong Z
Mol Med Rep; 2014 Apr; 9(4):1135-41. PubMed ID: 24566465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
